Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kintor Pharmaceutical Ltd ( (HK:9939) ) has issued an update.
Kintor Pharmaceutical Ltd has completed the enrollment of 130 subjects for a long-term human safety trial of KT-939, a novel tyrosinase inhibitor aimed at inhibiting melanin production. This trial is a critical step towards obtaining approval from the National Medical Products Administration in China for KT-939 as a new cosmetic raw material. The company aims to submit the registration application in the third quarter of next year, potentially marking a significant milestone in the Chinese and global whitening cosmetics market. Kintor is also seeking strategic collaborations with cosmetic brands to advance product development and market expansion.
More about Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Ltd is a company in the pharmaceutical industry, focusing on the development of novel therapeutic products. The company specializes in creating innovative solutions for medical and cosmetic applications, with a particular emphasis on products that inhibit melanin production.
Average Trading Volume: 7,086,497
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.09B
Find detailed analytics on 9939 stock on TipRanks’ Stock Analysis page.